Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis of two phase 3, randomized controlled trials (ESTEEM 1 and 2)

¹SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany,²Probity Medical Research, Waterloo, ON, Canada,³Northwestern University, Chicago, IL, U.S.A.,⁴Dermatology Centre, University of Manchester, Manchester, U.K.,⁵University of Rome Tor Vergata, Rome, Italy,⁶Hospital Universitario Fundacion Alcorcon, Madrid, Spain,⁷Tufts Medical Center, Boston, MA, U.S.A.,⁸Celgene Corporation, Warren, NJ, U.S.A. and⁹Toulouse University, Hôpital Larrey, Toulouse, France